Evidence map›Paper›PMID 32494856›Full record

ArticleJournal of neurology2020

COVID-19 in teriflunomide-treated patients with multiple sclerosis.

Amir Hadi Maghzi, Maria K Houtchens, Paolo Preziosa, Carolina Ionete, Biljana D Beretich, James M Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara H W Schwartz and 5 more

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Multiple sclerosis patients' response to COVID-19 pandemic and vaccination in Egypt.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Amir Hadi MaghziDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.
Maria K HoutchensDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.
Paolo PreziosaNeurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Carolina IoneteDepartment of Neurology, University of Massachusetts, Worcester, MA, USA.
Biljana D BeretichDepartment of Neurology, Maine Medical Center, Portland, ME, USA.
James M StankiewiczDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.
Shahamat TauhidDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.
Ann CabotDepartment of Neurology, Concord Hospital, Concord, NH, USA.
Idanis BerriosmoralesDepartment of Neurology, University of Massachusetts, Worcester, MA, USA.
Tamara H W SchwartzDepartment of Neurology, Maine Medical Center, Portland, ME, USA.
Jacob A SloaneDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Mark S FreedmanUniversity of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Massimo FilippiNeurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Howard L WeinerDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA.
Rohit BakshiDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Mailbox 9002L, Boston, MA, 02115, USA. rbakshi@post.harvard.edu.ORCID http://orcid.org/0000-0001-8601-5534
Brigham and Women's Hospital · USMaine Medical Center · USUniversity of Massachusetts Chan Medical School · USBeth Israel Deaconess Medical Center · USConcord Hospital · USIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Ottawa · CAVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.

Indexed as

AdultAgedBetacoronavirusCoronavirus InfectionsCOVID-19CrotonatesFemaleHumansHydroxybutyratesImmunosuppressive AgentsMaleMiddle AgedMultiple SclerosisNitrilesPandemicsPneumonia, ViralCrotonatesHydroxybutyratesImmunosuppressive AgentsNitrilesteriflunomideToluidinesAntiviralCoronavirusCOVID-19Multiple sclerosisTeriflunomide

Identifiers

PMID32494856
PMCPMC7268971
OpenAlexW3030121249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.